Ragini R. Kudchadkar
Daiichi Sankyo (Germany)(DE)Daiichi-Sankyo (South Korea)(KR)Daiichi Sankyo (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations(2012)2,783 cited
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,298 cited
- → PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma(2016)1,234 cited
- → Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma(2013)529 cited
- → Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma(2014)423 cited
- → Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial